Title : Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.

Pub. Date : 2021 Jul 28

PMID : 34360855






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. S63845 tet methylcytosine dioxygenase 2 Homo sapiens
2 The combination of the STAT5-inhibitor AC-4-130 and the MCL1 inhibitor S63845 may be an effective treatment targeting FLT3-mutated or TET2-mutated AML. S63845 tet methylcytosine dioxygenase 2 Homo sapiens